GHAZI ASAAD: Open Payments
NPI 1194767681 · DANBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,460 in 199 payments from 21 companies in 2025. Trend: 2023 $4,692 · 2024 $4,793 · 2025 $4,460
Food & beverage: $4,460
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 56 | $967 |
| Otsuka America Pharmaceutical, Inc. | 31 | $482 |
| Neurocrine BioSciences, Inc. | 15 | $453 |
| Teva Pharmaceuticals USA, Inc. | 15 | $379 |
| Corium, LLC | 17 | $317 |
| Janssen Pharmaceuticals, Inc | 12 | $306 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $281 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $266 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $217 |
| Axsome Therapeutics, Inc. | 8 | $204 |
Products named: VRAYLAR, INGREZZA, INVEGA SUSTENNA, REXULTI, Azstarys, TRINTELLIX, AUSTEDO XR, CAPLYTA.
Industry payments across CT — which companies pay providers there.
